{{Drugbox
| Watchedfields = changed
| verifiedrevid = 400115757
| IUPAC_name = Nonasodium (2''S'',3''S'',4''S'',5''R'',6''R'')-6-[(2''R'',3''R'',4''S'',5''R'',6''R'')-6-
| image = Idraparinux.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| routes_of_administration = Subcutaneous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 80-130 hours
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 149920-56-9
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 3083444
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2340656

<!--Chemical data-->
| chemical_formula =  
| C=38 | H=55 | Na=9 | O=49 | S=7 
| molecular_weight = 1727.17683 g/mol
| smiles = CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)[O-])O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)[O-])O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C38H64O49S7.9Na/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54;;;;;;;;;/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63);;;;;;;;;/q;9*+1/p-9/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-;;;;;;;;;/m1........./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MVPQUSQUURLQKF-MCPDASDXSA-E
}}
<!-- MeSHName=SANORG+34006 -->

'''Idraparinux sodium''' is an [[anticoagulant]] medication in development by [[Sanofi-Aventis]].<ref name="pmid18294998">{{cite journal  |vauthors=Bousser MG, Bouthier J, Büller HR, etal |title=Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial |journal=Lancet |volume=371 |issue=9609 |pages=315–21 |date=January 2008 |pmid=18294998 |doi=10.1016/S0140-6736(08)60168-3 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(08)60168-3}}</ref>

It has a similar chemical structure and the same method of action as [[fondaparinux]], but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week.

Sanofi discontinued the development of idraparinux sodium.

==Negative clinical trial==
A phase III trial of idraparinux sodium for stroke prevention in patients with AF (AMADEUS) was halted prematurely due to excessive clinically relevant and intracranial bleeding. Bleedings were particularly increased in elderly patients and those with renal impairment.  Sanofi discontinued the development of idraparinux sodium in favour of a biotinylated formulation of the drug called idrabiotaparinux sodium.<ref>Modern anticoagulants threaten status quo http://www.pmlive.com/pharma_intelligence/modern_anticoagulants_threaten_status_quo_411610</ref><ref>The Amadeus investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371:315-321. </ref>

==Method of action==
Idraparinux selectively blocks [[coagulation factor Xa]].<ref name="pmid17855670">{{cite journal  |vauthors=Buller HR, Cohen AT, Davidson B, etal |title=Idraparinux versus standard therapy for venous thromboembolic disease |journal=N. Engl. J. Med. |volume=357 |issue=11 |pages=1094–104 |date=September 2007 |pmid=17855670 |doi=10.1056/NEJMoa064247 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17855670&promo=ONFLNS19}}</ref>

See [[Heparin#Mechanism of anticoagulant action|Heparin: Mechanism of anticoagulant action]] for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.

== {{anchor|Idrabiotaparinux}} Idrabiotaparinux ==
Idrabiotaparinux sodium is also administered once-weekly. It has the same pentasaccharidic structure as idraparinux sodium, but with [[biotin]]
attached, which allows its neutralisation with [[avidin]], an egg-derived protein with low antigenicity.
Sanofi conducted three phase III trials of idrabiotaparinux sodium between 2006 and 2008 in approximately 13,550 patients. In one phase III trial (the BOREALIS-AF study), idrabiotaparinux sodium was non-inferior to warfarin in preventing the recurrent [[venous thromboembolism]] at three months in patients with pulmonary embolism and the incidence of clinically relevant bleeding was lower in the idrabiotaparinux sodium arm. The drug was expected to be filed for stroke prevention in patients with [[atrial fibrillation]] in 2011. The study was prematurely terminated, and the reason remains unclear.<ref>Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines  Luciana Armaganijan, Dimpi Patel, [...], and Carlos A. Morillo Pharmaceuticals (Basel). Apr 2012; 5(4): 384–397 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763643/#!po=2.63158 doi:  10.3390/ph5040384]</ref> However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing.<ref>Modern anticoagulants threaten status quo http://www.pmlive.com/pharma_intelligence/modern_anticoagulants_threaten_status_quo_411610</ref> A systematic review found that until now there is not sufficient evidence to clarify whether idraparinux or idrabiotaparinux are as effective and safe as the standard warfarin treatment for venous thromboembolism prevention. Idraparinux or idrabiotaparinux decreased major bleeding rate significantly but had a trend to increase the all-cause mortality compared with warfarin.<ref>Song Y, Li X, Pavithra S, Li D (2013) Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 8(11): e78972. [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0078972 doi:10.1371/journal.pone.0078972]</ref>

==References==
{{reflist}}

{{Antithrombotics}}

[[Category:Oligosaccharides]]
[[Category:Heparins]]